Evidence map›Paper›PMID 27857212›Full record

ArticleScientific reports2016

GR-independent down-modulation on GM-CSF bone marrow-derived dendritic cells by the selective glucocorticoid receptor modulator Compound A.

Andres E Barcala Tabarrozzi, Luz Andreone, Julie Deckers, Carla N Castro, María L Gimeno, Laura Ariolfo, Paula M Berguer, María Antunica-Noguerol, Ana C Liberman, Sabine Vettorazzi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. [Research progress of alpha-fetoprotein vaccine in hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Andres E Barcala TabarrozziInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Luz AndreoneInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Julie DeckersReceptor Research Laboratories, Nuclear Receptor Lab, VIB-Department of Medical Protein Research, VIB, Ghent University, Gent, Belgium.
Carla N CastroInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
María L GimenoInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Laura AriolfoInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Paula M BerguerFundación Instituto Leloir, IIBBA, CONICET, Buenos Aires, Argentina.
María Antunica-NoguerolInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Ana C LibermanInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Sabine VettorazziInstitute for Comparative Molecular Endocrinology, University of Ulm, Ulm, Germany.
Jan P TuckermannInstitute for Comparative Molecular Endocrinology, University of Ulm, Ulm, Germany.
Karolien De BosscherReceptor Research Laboratories, Nuclear Receptor Lab, VIB-Department of Medical Protein Research, VIB, Ghent University, Gent, Belgium.
Marcelo J PeroneInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Biomedicine Research Institute of Buenos Aires - CONICET - Partner Institute of the Max Planck Society · ARGhent University · BEUniversität Ulm · DEFundación Instituto Leloir · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cells (DC) initiate the adaptive immune response. Glucocorticoids (GCs) down-modulate the function of DC. Compound A (CpdA, (2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride) is a plant-derived GR-ligand with marked dissociative properties. We investigated the effects of CpdA on in vitro generated GM-CSF-conditioned bone marrow-derived DC (BMDC). CpdA-exposed BMDC exhibited low expression of cell-surface molecules and diminution of the release of proinflammatory cytokines upon LPS stimulation; processes associated with BMDC maturation and activation. CpdA-treated BMDC were inefficient at Ag capture via mannose receptor-mediated endocytosis and displayed reduced T-cell priming. CpdA prevented the LPS-induced rise in pErk1/2 and pP38, kinases involved in TLR4 signaling. CpdA fully inhibited LPS-induced pAkt

Indexed as

Down-RegulationAcetatesAnimalsB7-1 AntigenBone Marrow CellsDendritic CellsEndocytosisGranulocyte-Macrophage Colony-Stimulating FactorInflammation MediatorsLipopolysaccharidesMiceReceptors, GlucocorticoidToll-Like Receptor 4TyramineUp-Regulation2-(4-acetoxyphenyl)-2-chloro-N-methylethylamineAcetatesB7-1 AntigenGranulocyte-Macrophage Colony-Stimulating FactorInflammation MediatorsLipopolysaccharidesReceptors, GlucocorticoidTlr4 protein, mouseToll-Like Receptor 4Tyramine

Identifiers

PMID27857212
PMCPMC5114550
OpenAlexW2555509169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.